Validation of Unani Pharmacopoeial formulation- Sharbat Zūfā Murakkab in patientsof Suāl Ratab (Productive Cough)
Acta Pharma Reports · 05.09.2022 · 1 (2) · 4-8
DOI: 10.51470/apr.2022.01.02.04 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Pharma Reports, online erschienen am 28.09.2022. Verfasst von Nikhat Shaikh und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Suāl Ratab (Productive Cough) is a clinical entity characterised by excessive mucus production, cough, chest tightness, and sore throat, aligning with Unani concepts of Balgham (phlegmatic) predominance. Sharbat Zūfā Murakkab (SZM) is a classical compound formulation of hyssop and accessory drugs documented in Unani pharmacopoeia, purported to possess expectorant (Munaffis-e-Balgham), bronchospasmolytic, and anti-inflammatory properties.
Objective
To evaluate the clinical efficacy and safety of Sharbat Zūfā Murakkab in patients presenting with Suāl Ratab at a tertiary-level Unani institution.
Methods
A single-arm, open-label observational clinical trial was conducted at RRIUM Mumbai under the CCRUM protocol. One hundred and nine (109) consenting patients were enrolled; 92 completed the study. Standardised symptom scores (cough frequency, intensity, quantity of expectoration, sore throat, hoarseness, chest tightness) were recorded at baseline, 1st follow-up (approx. day 15), and 2nd follow-up/end of treatment (approx. day 30). Haematological parameters (Hb, TLC, ESR) and biochemical safety markers were assessed pre- and post-treatment. Outcome was categorised as Cured (CR), Relieved (RL), Partially Relieved (PRL), and Not Relieved (NRL). Wilcoxon signed-rank test was applied for within-group comparisons.
Results
Mean age was 41.3 ± 12.3 years (range 18–64); males predominated (87.9%). Balghami temperament (Mizaj) was present in 79.8% of cases. Among 92 evaluable patients, 41 (44.6%) were Cured, 29 (31.5%) Relieved, 15 (16.3%) Partially Relieved, and 7 (7.6%) Not Relieved — giving a combined positive response rate of 76.1% (CR+RL). All symptom scores showed statistically significant reduction from baseline to both follow-up visits (p < 0.0001). Mean cough frequency score fell from 2.37 to 0.74 (68.8% improvement). TLC declined significantly (p = 0.002) and ESR showed significant reduction (p = 0.014). No adverse events were recorded.
Conclusion
Sharbat Zūfā Murakkab demonstrated clinically meaningful and statistically significant benefit in Suāl Ratab, with a favourable safety profile. These findings support its validation as a pharmacopoeial Unani formulation for productive cough.
Zitieren
APA
Shaikh, N., Ahmed, I., Alam, S., Alam, M. M., Shah, A., & Sheeraz, M. (2022). Validation of Unani Pharmacopoeial formulation- Sharbat Zūfā Murakkab in patientsof Suāl Ratab (Productive Cough). Acta Pharma Reports, 1(2), 4-8. https://doi.org/10.51470/apr.2022.01.02.04
Vancouver
Shaikh N, Ahmed I, Alam S, Alam MM, Shah A, Sheeraz M. Validation of Unani Pharmacopoeial formulation- Sharbat Zūfā Murakkab in patientsof Suāl Ratab (Productive Cough). Acta Pharma Reports. 2022;1(2):4-8. doi:10.51470/apr.2022.01.02.04
BibTeX
@article{Shaikh2022,
author = {Shaikh, Nikhat and Ahmed, Irfan and Alam, Shah and Alam, MD Manzar and Shah, Arjumand and Sheeraz, Mohammed},
title = {Validation of Unani Pharmacopoeial formulation- Sharbat Zūfā Murakkab in patientsof Suāl Ratab (Productive Cough)},
journal = {Acta Pharma Reports},
year = {2022},
volume = {1},
number = {2},
pages = {4--8},
doi = {10.51470/apr.2022.01.02.04}
}
EUVIMED